πŸ‡ΊπŸ‡Έ FDA
Patent

US 8703730

Complement antagonists and uses thereof

granted A61KA61K31/136A61K31/7088

Quick answer

US patent 8703730 (Complement antagonists and uses thereof) held by REGENESANCE B.V. expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENESANCE B.V.
Grant date
Tue Apr 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/136, A61K31/7088, A61K31/785, A61K38/215